Clinical trials: Persistent Negative Symptoms
Endometrial Cancer
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
This is an open-label, multi-center, single-arm, two-period Phase 2 study. The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with recurrent or…
- Trial name
- NCT03077698
- Testing
- Sodium Cridanimod, progestin therapy
- Where
- 25 sites in United States
- Volunteers
- 25 people
- Sponsor
- Xenetic Biosciences, Inc.
Soil-transmitted Helminthiasis, Schistosomiasis
Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
NIDIAG is an international collaboration on integrated diagnosis-treatment platforms, funded by the European Commission (EC). NIDIAG aims to develop an improved, patient-centred system for delivering primary health care in…
- Conditions
- Soil-transmitted Helminthiasis, Schistosomiasis, Strongyloidiasis, Shigellosis
- Trial name
- NIDIAGDigest (NCT02105714)
- Testing
- Stool culturing for pathogenic bacteria, Kato-Katz technique, Baermann technique
- Where
- 7 sites in Côte d’Ivoire, Indonesia and 2 more
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Mental Disorders, Schizophrenia
STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia
This project aims to provide the proof of concept for transcranial direct-current stimulation (tDCS) in the treatment of resistant/persistent Schizophrenia symptoms.
- Trial name
- STIM'ZO (NCT02744989)
- Testing
- Neuroconn or Neuroelectric tDCS stimulator
- Where
- 10 sites in France, Monaco
- Volunteers
- 141 people
- Sponsor
- Hospices Civils de Lyon
Negative Symptoms of Schizophrenia
SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms…
- Trial name
- NSS (NCT01234298)
- Testing
- SPD489 Low-Dose, SPD489 High-Dose
- Sponsor
- Shire
Multiple Myeloma, Minimal Residual Disease
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
The aim of this study was to observe the rate of MRD conversion and the impact on survival in newly diagnosed multiple myeloma (NDMM) patients with persistent MRD positivity after induction and consolidation therapy (autologous…
- Trial name
- MRD (NCT06109233)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- FengYan Jin
Schizophrenia
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
- Trial name
- NCT00977522
- Testing
- PF-03463275
- Where
- 37 sites in United States
- Volunteers
- 207 people
- Sponsor
- Pfizer
Phantom Limb Pain After Amputation, Chronic Pain Due to Injury
Negative Pressure Wound Therapy as a Predictor of Persistent Pain After War-Related Trauma
War-related trauma frequently causes complex soft tissue injuries that require repeated surgical treatment and advanced wound management techniques such as Negative Pressure Wound Therapy (NPWT).
- Conditions
- Phantom Limb Pain After Amputation, Chronic Pain Due to Injury, Postoperative Pain, Trauma (Including Fractures)
- Trial name
- NPWT-Pain Stud (NCT07475897)
- Where
- Ukraine
- Volunteers
- 150 people
- Sponsor
- Charitable Organisation Charitable Fund Superhumans (Co Cf Superhumans)
Schizophrenia
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in participants with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192867
- Testing
- RO4917838, Antipshychotics (Standard of Care)
- Where
- 122 sites in United States, Argentina and 12 more
- Volunteers
- 629 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)
The purpose of this study is to determine whether MK-8435 (Org 25935) is more effective than placebo in improving negative symptoms in participants with schizophrenia who are concurrently treated with a stable dose of a second…
- Trial name
- GIANT (NCT00725075)
- Testing
- MK-8435 (Org 25935) 4-8 mg, MK-8435 (Org 25935) 12-16 mg
- Volunteers
- 215 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with persistent, predominant negative symptoms of…
- Trial name
- NCT01192880
- Testing
- Bitopertin, Antipsychotics
- Where
- 103 sites in United States, Bulgaria and 5 more
- Volunteers
- 625 people
- Sponsor
- Hoffmann-La Roche
Persistent Cough, Whooping Cough
Montelukast for Persistent Cough in Young People and Adults
Persistent cough is a common symptom, accounting for about 20% of referrals to outpatient chest clinics. Most coughs are caused by self-limiting viral infections such as the common cold.
- Trial name
- MAC (NCT01279668)
- Testing
- Montelukast
- Where
- United Kingdom
- Volunteers
- 276 people
- Sponsor
- University of Oxford
Schizophrenia
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms in patients with schizophrenia
- Trial name
- NCT03793712
- Testing
- Lu AF11167 (1-2 mg/day), Lu AF11167 (3-4 mg/day)
- Where
- 53 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 168 people
- Sponsor
- H. Lundbeck A/S
Post-Treatment Lyme Disease
Meditation and Kundalini Yoga for Persistent Lyme-related Symptoms - an Online Study
This randomized, controlled study examines whether a daily practice over 8 weeks of Kundalini Yoga or Meditation can help to reduce pain and/or fatigue among patients with symptoms that persist despite prior antibiotic treatment.
- Trial name
- NCT04349605
- Testing
- Meditation, Kundalini Yoga
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Lyme Disease, Borrelia Infection
Persistent Lyme Empiric Antibiotic Study Europe
The purpose of the study is to establish whether prolonged antibiotic treatment of patients diagnosed with proven or presumed PLD (as endorsed by the international ILADS guidelines) leads to better patient outcome than short-term…
- Trial name
- PLEASE (NCT01207739)
- Testing
- Doxycycline, Clarithromycin and hydroxychloroquine
- Where
- 2 sites in Netherlands
- Volunteers
- 280 people
- Sponsor
- Radboud University Medical Center
Schizophrenia
Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)
This project will conduct a confirmatory efficacy trial of two novel psychosocial interventions, Cognitive Enhancement Therapy and Enriched Supportive Therapy, for the treatment of persistent negative symptoms in schizophrenia.
- Trial name
- NCT04143126
- Testing
- Cognitive Enhancement Therapy, Enriched Supportive Therapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Pittsburgh
Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa
Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection
The use of inhaled medications for the treatment of pulmonary diseases allows for the delivery of a high concentration of a drug at the site of disease with reduced systemic absorption and risk of systemic adverse effects.
- Trial name
- TOBI (NCT02102152)
- Testing
- Tobramycin
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rabin Medical Center
Post-Treatment Lyme Disease Syndrome
Ceftriaxone for Post-Treatment Lyme Disease
Lyme disease is a public health crisis in the US. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop Post-Treatment Lyme disease Syndrome (PTLDS).
- Trial name
- NCT06785402
- Testing
- Ceftriaxone treatment
- Where
- United States
- Sponsor
- Hackensack Meridian Health
Cervix, Dysplasia, HPV Infection
Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
A retrospective cohort study of women treated by excisional therapy due to HSIL/ CIN at Clínico San Carlos Hospital between 2012-2018.
- Conditions
- Cervix, Dysplasia, HPV Infection, HPV Vaccine, Cervix Lesion
- Trial name
- VENUS (NCT04171505)
- Testing
- HPV vaccine
- Where
- Spain
- Volunteers
- 508 people
- Sponsor
- Hospital San Carlos, Madrid
Schizophrenia
Treatment Development Targeting Severe and Persistent Negative Symptoms
People with schizophrenia often have problems with negative symptoms; expressing and identifying their emotions, their amount of speech, motivation and interests, feelings of purpose, social skills, and experiencing enjoyment.
- Trial name
- MOVE (NCT01550666)
- Testing
- MOVE
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192906
- Testing
- bitopertin [RO4917838]
- Where
- 113 sites in United States, Brazil and 12 more
- Volunteers
- 624 people
- Sponsor
- Hoffmann-La Roche